Evidence map›Paper›PMID 33215304›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2021

Identification of the immune gene expression signature associated with recurrence of high-grade gliomas.

Adria-Jaume Roura, Bartlomiej Gielniewski, Paulina Pilanc, Paulina Szadkowska, Marta Maleszewska, Sylwia K Krol, Ryszard Czepko, Wojciech Kaspera, Bartosz Wojtas, Bozena Kaminska

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. New insights into the molecular genetics of recurrent malignant gliomas.Journal of molecular medicine (Berlin, Germany) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Adria-Jaume RouraNencki Institute of Experimental Biology, Warsaw, Poland.ORCID https://orcid.org/0000-0002-8271-8803
Bartlomiej GielniewskiNencki Institute of Experimental Biology, Warsaw, Poland.ORCID https://orcid.org/0000-0001-8067-0618
Paulina PilancNencki Institute of Experimental Biology, Warsaw, Poland.
Paulina SzadkowskaNencki Institute of Experimental Biology, Warsaw, Poland.ORCID https://orcid.org/0000-0001-8125-4843
Marta MaleszewskaNencki Institute of Experimental Biology, Warsaw, Poland.ORCID https://orcid.org/0000-0001-8695-374X
Sylwia K KrolNencki Institute of Experimental Biology, Warsaw, Poland.ORCID https://orcid.org/0000-0002-5297-9033
Ryszard CzepkoClinical Department of Neurosurgery, St. Raphael Hospital, Andrzej Frycz Modrzewski Krakow University, Krakow, Poland.ORCID https://orcid.org/0000-0003-3872-1201
Wojciech KasperaDepartment of Neurosurgery, Regional Hospital, Medical University of Silesia, Sosnowiec, Poland.ORCID https://orcid.org/0000-0002-7139-3409
Bartosz WojtasNencki Institute of Experimental Biology, Warsaw, Poland. b.wojtas@nencki.edu.pl.ORCID https://orcid.org/0000-0002-9967-910X
Bozena KaminskaNencki Institute of Experimental Biology, Warsaw, Poland.ORCID https://orcid.org/0000-0002-2642-4616
Instytut Biologii Doświadczalnej im. Marcelego Nenckiego · PLAndrzej Frycz Modrzewski Krakow University · PLMedical University of Silesia · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-grade gliomas (HGGs), the most common and aggressive primary brain tumors in adults, inevitably recur due to incomplete surgery or resistance to therapy. Intratumoral genomic and cellular heterogeneity of HGGs contributes to therapeutic resistance, recurrence, and poor clinical outcomes. Transcriptomic profiles of HGGs at recurrence have not been investigated in detail. Using targeted sequencing of cancer-related genes and transcriptomics, we identified single nucleotide variations, small insertions and deletions, copy number aberrations (CNAs), as well as gene expression changes and pathway deregulation in 16 pairs of primary and recurrent HGGs. Most of the somatic mutations identified in primary HGGs were not detected after relapse, suggesting a subclone substitution during the tumor progression. We found a novel frameshift insertion in the ZNF384 gene which may contribute to extracellular matrix remodeling. An inverse correlation of focal CNAs in EGFR and PTEN genes was detected. Transcriptomic analysis revealed downregulation of genes involved in messenger RNA splicing, cell cycle, and DNA repair, while genes related to interferon signaling and phosphatidylinositol (PI) metabolism are upregulated in secondary HGGs when compared to primary HGGs. In silico analysis of the tumor microenvironment identified M2 macrophages and immature dendritic cells as enriched in recurrent HGGs, suggesting a prominent immunosuppressive signature. Accumulation of those cells in recurrent HGGs was validated by immunostaining. Our findings point to a substantial transcriptomic deregulation and a pronounced infiltration of immature dendritic cells in recurrent HGG, which may impact the effectiveness of frontline immunotherapies in the GBM management. KEY MESSAGES: Most of the somatic mutations identified in primary HGGs were not detected after relapse. Focal CNAs in EGFR and PTEN genes are inversely correlated in primary and recurrent HGGs. Transcriptomic changes and distinct immune-related signatures characterize HGG recurrence. Recurrent HGGs are characterized by a prominent infiltration of immature dendritic and M2 macrophages.

Indexed as

AdultAgedBrain NeoplasmsDendritic CellsDNA Copy Number VariationsErbB ReceptorsFemaleGliomaHumansMacrophagesMaleMiddle AgedMutationNeoplasm Recurrence, LocalPTEN PhosphohydrolaseTrans-ActivatorsEGFR protein, humanErbB ReceptorsPTEN PhosphohydrolasePTEN protein, humanTrans-ActivatorsZNF384 protein, humanCopy number aberrationsImmune signatureImmunohistochemistryRecurrent high-grade gliomaTumor microenvironment

Identifiers

PMID33215304
OpenAlexW3103964782

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.